GB0721095D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB0721095D0
GB0721095D0 GBGB0721095.8A GB0721095A GB0721095D0 GB 0721095 D0 GB0721095 D0 GB 0721095D0 GB 0721095 A GB0721095 A GB 0721095A GB 0721095 D0 GB0721095 D0 GB 0721095D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0721095.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramed Ltd
Original Assignee
Piramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramed Ltd filed Critical Piramed Ltd
Priority to GBGB0721095.8A priority Critical patent/GB0721095D0/en
Publication of GB0721095D0 publication Critical patent/GB0721095D0/en
Priority to CN2008801126921A priority patent/CN101868464B/zh
Priority to US12/739,435 priority patent/US8293735B2/en
Priority to ES08842778.6T priority patent/ES2442501T3/es
Priority to JP2010530548A priority patent/JP5675360B2/ja
Priority to EP08842778.6A priority patent/EP2205610B1/en
Priority to PCT/GB2008/003621 priority patent/WO2009053715A1/en
Priority to CA2701276A priority patent/CA2701276A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0721095.8A 2007-10-26 2007-10-26 Pharmaceutical compounds Ceased GB0721095D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0721095.8A GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds
CN2008801126921A CN101868464B (zh) 2007-10-26 2008-10-27 作为pi3抑制剂的噻吩并嘧啶衍生物
US12/739,435 US8293735B2 (en) 2007-10-26 2008-10-27 Thienopyrimidine derivatives as P13K inhibitors
ES08842778.6T ES2442501T3 (es) 2007-10-26 2008-10-27 Derivados de tienopirimidina como inhibidores de PI3K
JP2010530548A JP5675360B2 (ja) 2007-10-26 2008-10-27 Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体
EP08842778.6A EP2205610B1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors
PCT/GB2008/003621 WO2009053715A1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors
CA2701276A CA2701276A1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0721095.8A GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB0721095D0 true GB0721095D0 (en) 2007-12-05

Family

ID=38830047

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0721095.8A Ceased GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds

Country Status (8)

Country Link
US (1) US8293735B2 (enExample)
EP (1) EP2205610B1 (enExample)
JP (1) JP5675360B2 (enExample)
CN (1) CN101868464B (enExample)
CA (1) CA2701276A1 (enExample)
ES (1) ES2442501T3 (enExample)
GB (1) GB0721095D0 (enExample)
WO (1) WO2009053715A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2451811A1 (en) * 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
EP2890698B1 (en) * 2012-08-30 2017-03-01 F. Hoffmann-La Roche AG Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
US10591000B2 (en) * 2016-05-24 2020-03-17 Means Industries, Inc. One-way clutch assembly and coupling member for therein wherein locking member dynamics with respect to strut laydown speed are enhanced
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AU2019416623B2 (en) * 2018-12-27 2022-12-08 Holosmedic Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
KR102338609B1 (ko) * 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN114127062A (zh) * 2019-05-31 2022-03-01 伊迪亚生物科学有限公司 作为DNA聚合酶Theta抑制剂的噻二唑基衍生物
BR112022007998A2 (pt) * 2019-10-31 2022-07-05 Holosmedic Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos
CN112920199B (zh) * 2020-06-02 2023-02-03 四川大学 一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (enExample) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
AU3053999A (en) * 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US20020156601A1 (en) * 2001-04-19 2002-10-24 Tu Kevin Hsiaohsu Event monitoring and detection system
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
BRPI0710866A2 (pt) * 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
CN101479274B (zh) * 2006-04-26 2013-06-12 霍夫曼-拉罗奇有限公司 药用化合物
RU2439074C2 (ru) * 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
JP5291616B2 (ja) * 2006-04-26 2013-09-18 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
JP5500990B2 (ja) * 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
ES2399774T3 (es) * 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
EP2214675B1 (en) * 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
EP2215090B1 (en) 2007-10-26 2015-03-04 F. Hoffmann-La Roche AG Purine derivatives useful as pi3 kinase inhibitors
US8158624B2 (en) * 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
SG175708A1 (en) * 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2451811A1 (en) * 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Also Published As

Publication number Publication date
EP2205610A1 (en) 2010-07-14
JP2011500774A (ja) 2011-01-06
JP5675360B2 (ja) 2015-02-25
EP2205610B1 (en) 2013-11-20
CN101868464A (zh) 2010-10-20
CN101868464B (zh) 2013-11-13
US8293735B2 (en) 2012-10-23
CA2701276A1 (en) 2009-04-30
WO2009053715A1 (en) 2009-04-30
US20110021496A1 (en) 2011-01-27
ES2442501T3 (es) 2014-02-11
WO2009053715A8 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
GB0709031D0 (en) Pharmaceutical compounds
IL201366A0 (en) Pharmaceutical compounds
ZA201104336B (en) Pharmaceutical compounds
GB0707087D0 (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
GB0725214D0 (en) Pharmaceutical compounds
GB0704932D0 (en) Pharmaceutical compounds
GB0816371D0 (en) Pharmaceutical compounds
GB0812969D0 (en) Pharmaceutical compounds
GB0721669D0 (en) Pharmaceutical compounds
PT2271618E (pt) Compostos farmacêuticos
GB0816370D0 (en) Pharmaceutical compounds
GB0810857D0 (en) Pharmaceutical compounds
GB0718045D0 (en) Pharmaceutical compound
GB0608176D0 (en) Pharmaceutical Compounds
GB0608184D0 (en) Pharmaceutical compounds
GB0608264D0 (en) Pharmaceutical compounds
GB0608175D0 (en) Pharmaceutical Compounds
GB0711346D0 (en) Pharmaceutical compounds
GB0715677D0 (en) Pharmaceutical compounds
GB0715676D0 (en) Pharmaceutical compounds
GB0711344D0 (en) Pharmaceutical compounds
GB0716798D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)